CN102552436B - Medicine for treating anxiety and depressive disorder as well as application of medicine - Google Patents
Medicine for treating anxiety and depressive disorder as well as application of medicine Download PDFInfo
- Publication number
- CN102552436B CN102552436B CN201210005314.1A CN201210005314A CN102552436B CN 102552436 B CN102552436 B CN 102552436B CN 201210005314 A CN201210005314 A CN 201210005314A CN 102552436 B CN102552436 B CN 102552436B
- Authority
- CN
- China
- Prior art keywords
- medicine
- parts
- anxiety
- treatment
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine for treating anxiety and depressive disorder, which is prepared by the following crude medicines according to parts by weight: 6-20 parts of radix bupleuri, 6-20 parts of radix paeoniae alba and 6-15 parts of white atractylodes rhizome; and the medicine further comprises 6-15 parts of selfheal, 3-6 parts of coptis chinensis and 3-6 parts of cinnamon. The invention further provides an application of the medicine in preparing medicine for treating anxiety and depressive disorder. The medicine is prepared by pure traditional Chinese medicine and based on enough traditional Chinese medicine and western medicine theories; the anxiety and depressive disorder is treated by concerning the morbidity background of the whole disease and the causa morbi and mechanism instead of being treated by the description of the disease; the curative effect is obvious by going deep into the base; the medicine has the same medicine strength as western medicine, so the medicine has no toxic or side effects; the medicine is easily accepted by sufferers; and with the advantages of less crude medicine components, easiness in obtaining, low cost and simple preparation process, the medicine can be popularized and used.
Description
Technical field
The present invention relates to a kind of medicine and application thereof for the treatment of anxiety-depression obstacle, specifically, is the Chinese patent medicine of making take Chinese herbal medicine as raw material.
Background technology
Anxiety-depression obstacle (anxiety and depressive disorder) has become the commonly encountered diseases of China.Anxiety disorder refers to a kind of to lack the on tenterhooks of clear and definite object and particular content, and nervous be main anxiety neurosis, patient is insecure all day, worry oneself work, health, are in fear of accident at worry relatives' safety, and often with body sense of discomfort; Depressive disorder refers to a kind of pessimism and the sense of loss, blunt to event response, aprosexia, and expression is sluggish, affective disorder.Meanwhile, anxiety-depression obstacle person 98% is with this somatization of insomnia, and sleep is the performance factor of outbalance in anxiety-depression obstacle.
At present, doctor trained in Western medicine there is no final conclusion completely for the etiology and pathogenesis of anxiety-depression obstacle, in its pathogeny, doctor trained in Western medicine thinks that central nervous system's biochemical function is closely related extremely with it, and relate generally to the neurotransmitteies such as NE, 5-HT, in addition, also think that anxiety disorder may be relevant with Benzodiazepine receptoroid etc.The not disease name corresponding with anxiety-depression obstacle of the traditional Chinese medical science, anxiety-depression obstacle belongs to the category of traditional Chinese medical science cardiopathia in fact, similar to " strongly fragrant disease ", " being insomnia ", " cardiopalmus " in the traditional Chinese medical science, " palpitation with a distress feeling " etc.The traditional Chinese medical science is mainly divided into two aspects, i.e. excess syndrome and deficiency syndrome to the etiology and pathogenesis research of anxiety depressive disorder at present.Excess syndrome mainly contains: is worried excessively, and functional activity of QI being not smooth, hepatic depression heat-transformation of a specified duration, upsets the mind; The stagnation of QI Tianjin is coagulated for expectorant, and mental disorder is handed over resistance, lack of preservation of spirit; The melancholy of feelings will, the liver failing to maintain the normal flow of QI, with the passing of time fire-transformation of the gas of having a surplus, refining liquid becomes expectorant, and gas, expectorant, heat, knot are hoodwinked the mind; Be worried depressed, qi depression to blood stasis, heat-transformation of a specified duration is lit a fire, follow through on disturb, malaise.Except depression of liver-QI, excessive rising of liver-YANG, liver-wind stirring up internally, also can the disturbance mind cause anxiety.Deficiency syndrome mainly contain: are worried excessively, can cause deficiency of both the heart and spleen, the heart and become homeless fosterly, secretly consume cloudy blood, and conscience deficiency of YIN-blood, the liver losing its smoothly moving state or liver-yang are partially high, and soul is difficult to hide, and god is without appended; Liver-blood deficiency courage is also empty, resolution dereliction of duty; The unsuccessful troubled thoughts of feelings will are immoderate, and the QI and blood consumption wound of the heart, can cause courage virtual loss; If undermine cloudy essence, the heart, gallbladder, liver, kidney all can be got involved.The moon sun not processed, asthenic fire disturbance, makes abnormal mind.
Research is discovery also, and anxiety-depression obstacle and cardiovascular disease are closely related.For example, the nineties in 20th century, the incidence rate of Shanghai Comprehensive hospital outpatient patients ' psychological obstacle was 10% ~ 20%, and inpatient 20% ~ 50%, and wherein cardiovascular diseases 40% ~ 50% is mainly anxiety disorder and depressive disorder; Having in the crowd of depressed and anxiety disorder, hypertensive incidence rate increases twice, and the danger of apoplexy, angina pectoris and myocardial infarction increases by 6 times, more than mortality rate increase twice.Comprehensive analysis, the pathophysiological mechanism that depression causes cardiovascular diseases at least comprises three aspects:: the first, cause high steroid 17-hydroxy-11-dehydrocorticosterone mass formed by blood stasis (the reaction aggravation of adrenal cortex to 17-hydroxy-11-dehydrocorticosterone releasing factor); The second, cause platelet function impaired, comprise that platelet response degree increases, the release of platelet material.These two kinds of machine-processed combinations have formed the basis of the atherogenic pathophysiological mechanism of depression.The 3rd, patients with depression heart rate variability degree reduces and autonomic nervous dysfunction, causes suffering from arrhythmia person and increases.Anxiety neurosis and coronary heart disease are also closely related, have researcher to think that anxiety patient heart rate variability degree reduces, and the pathologic of reflection vegetative nerve tension force changes.This change causes sympathetic irritation to increase (thereby causing arrhythmia and sudden death), or causes autonomic nervous dysfunction, causes cardiac death.Autonomic nervous dysfunction can cause the cardiac pressure sensitivity reflex function imbalance being mediated by vegetative nerve and cause sudden death.
From the Pathophysiology pathogenesis of Anxiety depression and cardiovascular disease, we can clearly find out, both identical points are with vegetative nerve function closely related.The change that both cause cardiac function is all because autonomic nervous dysfunction causes.In theory, the plus-minus treatment Anxiety depression rule for the treatment of can be first to give tranquilizing by nourishing the heart, rear liver-smoothing, qi-regulating.By tranquilizing by nourishing the heart method, improve patient autonomic nervous dysfunction, improve patient's cardiovascular related symptoms and sleep symptom, thus treatment anxiety-depression obstacle.
At present, on the western medical treatment of depression, deanxit is widely used in treating Combination anxiety-depression obstacle.The mixture that deanxit is comprised of low dose of flupentixol and low dose of melitracen, its pharmacological action is the result of two kinds of composition comprehensive functions, be mainly manifested in it and improve synaptic space dopamine, the content of the various neurotransmitters such as norepinephrine and 5-hydroxytryptamine, entirety central nervous system's function, in addition, it has certain antagonism to Histamine receptors, there is analgesia, anticonvulsant action.It is similar to Benzodiazepines with somatization that clinical discovery deanxit improves anxiety, but it also has the depressed effect of improvement preferably.But its relatively limitation part be, deanxit bans use of in there being serious heart disease to recover early stage, bundle branch block as myocardial infarction; Untreated narrow angle property glaucoma; The patient of fever; Acute alcohol, barbiturate and meconism; Trimester of pregnancy and women breast-feeding their children; For Cardiological there is certain limitation in medication, because gerontal patient's bundle branch block is more, most of patients there is no clear and definite main suit, therefore easily cause malpractice.In the traditional Chinese medical science, the medicine for the treatment of anxiety-depression obstacle is added up after deliberation its medicine law and is: by frequency of usage height, be followed successively by Poria 39 times, Radix Glycyrrhizae 31 times, Semen Ziziphi Spinosae 29 times, Radix Bupleuri 25 times, Radix Polygalae 24 times, Radix Angelicae Sinensis 22 times, Fructus Schisandrae Chinensis 19 times, Os Draconis 17 times, Radix Ginseng 16 times, the Radix Paeoniae Alba 16 times, the Rhizoma Pinelliae 16 times, Radix Rehmanniae Preparata 16 times, Radix Rehmanniae 15 times, Radix Ophiopogonis 15 times, Radix Asparagi 15, Radix Salviae Miltiorrhizae 12 times, Semen Platycladi 11 times, Radix Curcumae 11 times, Rhizoma Acori Graminei 11 times.Wherein, the medicine with sedative action has Poria, Semen Ziziphi Spinosae, Radix Polygalae, Fructus Schisandrae Chinensis, Os Draconis, Radix Salviae Miltiorrhizae, Semen Platycladi, Rhizoma Acori Graminei etc., reaches more than 8 tastes; The medicine with replenishing YIN and blood effect has 6 tastes such as Radix Angelicae Sinensis, the Radix Paeoniae Alba, Radix Rehmanniae Preparata, Radix Rehmanniae, Radix Ophiopogonis, Radix Asparagi; From the utilization rate of said medicine, can know in treatment anxiety-depression obstacle, widely applied calm the nerves, the agent of replenishing YIN and blood, embodied the traditional Chinese medical science and focused on the treatment to this disease irritability primary symptom, take into account the administration features of deficiency of YIN-blood simultaneously.
Chinese patent literature CN 200910019713.1, June 15 2011 day for announcing, a kind of Cure of depression is disclosed, Chinese medicine preparation of anxiety neurosis and preparation method thereof, this Chinese medicine preparation is made by the important source material of following ratio of weight and number: Radix Rehmanniae Preparata 10-30 part, Flos Albiziae 10-30 part, Semen Platycladi 10-30 part, Rhizoma Cyperi 10-30 part, Radix Bupleuri 10-30 part, Rhizoma Dioscoreae 10-30 part, Radix Polygoni Multiflori Preparata 10-30 part, Herb Gynostemmae Pentaphylli 10-30 part, Fructus Gardeniae 10-30 part, Radix Codonopsis 10-30 part, Radix Angelicae Sinensis 10-30 part, Concha Ostreae 10-30 part, Radix Astragali 10-30 part, Fructus Schisandrae Chinensis 10-30 part, Herba Epimedii 10-30 part, Semen Ziziphi Spinosae 10-30 part, Radix Polygalae 10-30 part, Cortex Phellodendri 10-30 part, Herba Anoectochili roxburghii 10-30 part, Ramulus Uncariae Cum Uncis 10-30 part, Chinese patent literature CN 02129417.2, January 26 2005 day for announcing, disclose the Chinese medicine preparation of a kind of Cure of depression, anxiety neurosis, this Chinese medicine preparation is to be made by the raw material of following weight proportioning: Radix Et Caulis Acanthopanacis Senticosi 10-100 part, Fructus Schisandrae Chinensis 10-100 part, Fructus Gardeniae 5-60 part, Radix Curcumae 3-60 part.The Chinese medicine composition for the treatment of depressive anxiety obstacle like that has a lot, but has shortcoming more or less, and for example, flavour of a drug are too much, and the difficulty of drawing materials is expensive; Drug effect is not obvious, and therapeutic effect is poor etc.Therefore, need badly a kind of treat depressive anxiety obstacle successful, flavour of a drug number moderate, be convenient to the medicine of preparation, but about this class medicine, have not been reported at present.
Summary of the invention
The object of the invention is for deficiency of the prior art, a kind of medicine for the treatment of depressive anxiety obstacle is provided.
One object more of the present invention is that a kind of purposes of medicine for the treatment of depressive anxiety obstacle is provided.
For achieving the above object, the technical scheme that the present invention takes is:
Treat a medicine for anxiety-depression obstacle, it is mainly to be made by the crude drug of following weight portion: Radix Bupleuri 6-20 part, Radix Paeoniae Alba 6-20 part, Rhizoma Atractylodis Macrocephalae 6-15 part.
If described drug main is made by the crude drug of following weight portion: Radix Bupleuri 10-16 part, Radix Paeoniae Alba 10-16 part, Rhizoma Atractylodis Macrocephalae 8-12 part.
If described drug main is made by the crude drug of following weight portion: 13 parts of Radix Bupleuri, 13 parts of the Radix Paeoniae Albas, 10 parts of the Rhizoma Atractylodis Macrocephalaes.
Described medicine also comprises the crude drug of following weight portion: Spica Prunellae 6-15 part.
The weight portion of described Spica Prunellae is 8-12 part.
The weight portion of described Spica Prunellae is 10 parts.
Described medicine also comprises the crude drug of following weight portion: Rhizoma Coptidis 3-6 part, Cortex Cinnamomi 3-6 part.
The weight portion of described Rhizoma Coptidis is 4.5 parts, and the weight portion of described Cortex Cinnamomi is 4.5 parts.
The medicament of described medicine is capsule, granule, tablet, oral liquid, mixture or syrup.
For realizing above-mentioned second object, the technical scheme that the present invention takes is:
The application of described medicine in preparation treatment anxiety-depression obstacle medicine.
The invention has the advantages that:
1, medicine of the present invention is on the traditional Chinese medical science and doctor trained in Western medicine theoretical basis based on sufficient, for the treatment of anxiety-depression obstacle, be not be only directed to the description of disease and carry out diagnosis and treatment, more pathogenetic background and the etiology and pathogenesis thereof of paying close attention to whole disease, go deep into it basic, curative effect is obvious, with Western medicine worthy opponent;
2, medicine of the present invention is made by pure Chinese medicine, has no side effect, and is easy to be accepted by patient;
3, medicine material component of the present invention is few, and abundant raw materials is easy to get, low price, and preparation technology is simple, is applicable to promoting the use of.
Accompanying drawing explanation
Accompanying drawing 1 is anxiety-depression obstacle age of onset and sickness rate graph of a relation.
Below in conjunction with accompanying drawing, the specific embodiment provided by the invention is elaborated.
embodiment 1 treats the preparation () of anxiety-depression obstacle medicine one
6 parts of Radix Bupleuri, 20 parts of the Radix Paeoniae Albas, 6 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts.
embodiment 2 treats the preparation (two) of anxiety-depression obstacle medicine one
20 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 15 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts.
embodiment 3 treats the preparation (three) of anxiety-depression obstacle medicine one
6 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 15 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts.
embodiment 4 treats the preparation (four) of anxiety-depression obstacle medicine one
20 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 6 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts.
embodiment 5 treats the preparation (five) of anxiety-depression obstacle medicine one
20 parts of Radix Bupleuri, 20 parts of the Radix Paeoniae Albas, 6 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts.
embodiment 6 treats the preparation (six) of anxiety-depression obstacle medicine one
13 parts of Radix Bupleuri, 13 parts of the Radix Paeoniae Albas, 10 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts.
embodiment 7 treats the preparation (seven) of anxiety-depression obstacle medicine one
10 parts of Radix Bupleuri, 16 parts of the Radix Paeoniae Albas, 8 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts.
embodiment 8 treats the preparation (eight) of anxiety-depression obstacle medicine one
16 parts of Radix Bupleuri, 10 parts of the Radix Paeoniae Albas, 12 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts.
embodiment 9 treats the preparation (nine) of anxiety-depression obstacle medicine one
20 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 12 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts.
embodiment 10 treats the preparation (ten) of anxiety-depression obstacle medicine one
10 parts of Radix Bupleuri, 10 parts of the Radix Paeoniae Albas, 8 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts.
embodiment 11 treats the preparation () of anxiety-depression obstacle medicine two
6 parts of Radix Bupleuri, 20 parts of the Radix Paeoniae Albas, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Spica Prunellaes, conventional method decocts.
embodiment 12 treats the preparation (two) of anxiety-depression obstacle medicine two
20 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 6 parts of Spica Prunellaes, conventional method decocts.
embodiment 13 treats the preparation (three) of anxiety-depression obstacle medicine two
6 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Spica Prunellaes, conventional method decocts.
embodiment 14 treats the preparation (four) of anxiety-depression obstacle medicine two
20 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Spica Prunellaes, conventional method decocts.
embodiment 15 treats the preparation (five) of anxiety-depression obstacle medicine two
20 parts of Radix Bupleuri, 20 parts of the Radix Paeoniae Albas, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Spica Prunellaes, conventional method decocts.
embodiment 16 treats the preparation (six) of anxiety-depression obstacle medicine two
13 parts of Radix Bupleuri, 13 parts of the Radix Paeoniae Albas, 10 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Spica Prunellaes, conventional method decocts.
embodiment 17 treats the preparation (seven) of anxiety-depression obstacle medicine two
10 parts of Radix Bupleuri, 16 parts of the Radix Paeoniae Albas, 8 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Spica Prunellaes, conventional method decocts.
embodiment 18 treats the preparation (eight) of anxiety-depression obstacle medicine two
16 parts of Radix Bupleuri, 10 parts of the Radix Paeoniae Albas, 12 parts of the Rhizoma Atractylodis Macrocephalaes, 12 parts of Spica Prunellaes, conventional method decocts.
embodiment 19 treats the preparation (nine) of anxiety-depression obstacle medicine two
20 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 12 parts of the Rhizoma Atractylodis Macrocephalaes, 8 parts of Spica Prunellaes, conventional method decocts.
embodiment 20 treats the preparation (ten) of anxiety-depression obstacle medicine two
10 parts of Radix Bupleuri, 10 parts of the Radix Paeoniae Albas, 8 parts of the Rhizoma Atractylodis Macrocephalaes, 12 parts of Spica Prunellaes, conventional method decocts.
embodiment 21 treats the preparation () of anxiety-depression obstacle medicine three
6 parts of Radix Bupleuri, 20 parts of the Radix Paeoniae Albas, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Spica Prunellaes, 3 parts of Rhizoma Coptidis, 6 parts of Cortex Cinnamomis, conventional method decocts.
embodiment 22 treats the preparation (two) of anxiety-depression obstacle medicine three
20 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 6 parts of Spica Prunellaes, 6 parts of Rhizoma Coptidis, 3 parts of Cortex Cinnamomis, conventional method decocts.
embodiment 23 treats the preparation (three) of anxiety-depression obstacle medicine three
6 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Spica Prunellaes, 6 parts of Rhizoma Coptidis, 3 parts of Cortex Cinnamomis, conventional method decocts.
embodiment 24 treats the preparation (four) of anxiety-depression obstacle medicine three
20 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Spica Prunellaes, 3 parts of Rhizoma Coptidis, 3 parts of Cortex Cinnamomis, conventional method decocts.
embodiment 25 treats the preparation (five) of anxiety-depression obstacle medicine three
20 parts of Radix Bupleuri, 20 parts of the Radix Paeoniae Albas, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Spica Prunellaes, 3 parts of Rhizoma Coptidis, 6 parts of Cortex Cinnamomis, conventional method decocts.
embodiment 26 treats the preparation (six) of anxiety-depression obstacle medicine three
13 parts of Radix Bupleuri, 13 parts of the Radix Paeoniae Albas, 10 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Spica Prunellaes, 4.5 parts of Rhizoma Coptidis, 4.5 parts of Cortex Cinnamomis, conventional method decocts.
embodiment 27 treats the preparation (seven) of anxiety-depression obstacle medicine three
10 parts of Radix Bupleuri, 16 parts of the Radix Paeoniae Albas, 8 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Spica Prunellaes, 5 parts of Rhizoma Coptidis, 4 parts of Cortex Cinnamomis, conventional method decocts.
embodiment 28 treats the preparation (eight) of anxiety-depression obstacle medicine three
16 parts of Radix Bupleuri, 10 parts of the Radix Paeoniae Albas, 12 parts of the Rhizoma Atractylodis Macrocephalaes, 12 parts of Spica Prunellaes, 4 parts of Rhizoma Coptidis, 5 parts of Cortex Cinnamomis, conventional method decocts.
embodiment 29 treats the preparation (nine) of anxiety-depression obstacle medicine three
20 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 12 parts of the Rhizoma Atractylodis Macrocephalaes, 8 parts of Spica Prunellaes, 4 parts of Rhizoma Coptidis, 4 parts of Cortex Cinnamomis, conventional method decocts.
embodiment 30 treats the preparation (ten) of anxiety-depression obstacle medicine three
10 parts of Radix Bupleuri, 10 parts of the Radix Paeoniae Albas, 8 parts of the Rhizoma Atractylodis Macrocephalaes, 12 parts of Spica Prunellaes, 5 parts of Rhizoma Coptidis, 6 parts of Cortex Cinnamomis, conventional method decocts.
It should be noted that, it is the manufacture method of Chinese medicine decoction routine that the conventional method described in embodiment 1-30 decocts, and is about to described crude drug and decocts with water into decoction.
embodiment 31 treats the preparation of anxiety-depression obstacle medicinal tablet/capsule
Get the arbitrary described medicine of embodiment 1-30, add 9-11 times of water gaging, decoct 2-3.5 hour, leach medicine juice.Add again 9 times of water gagings, decoct 2.5 hours, leach medicine juice, merge secondary decocting liquid, standing, leaching supernatant, concentrated, let cool, add 3 times of amount ethanol of concentrated solution, stir precipitation and spend the night.Get supernatant, be concentrated into thick extractum; Add pharmaceutical aids, vacuum drying, pulverizes and granulates, and is pressed into tablet or fills encapsulated.
embodiment 32 treats the preparation of anxiety-depression obstacle drug particles
get the arbitrary described medicine of embodiment 1-30, add 8-10 times of water gaging, decoct 3 hours, leach medicine juice.Add again 10 times of water gagings, decoct 2.5 hours, leach medicine juice, merge secondary decocting liquid, standing, leaching supernatant, concentrated, let cool, add 2 times of amount ethanol of concentrated solution, stir precipitation and spend the night.Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids, granulate, dry, granulate, obtains 20g granule, subpackage 10g/ bag.
embodiment 33 treats the preparation of anxiety-depression obstacle drug mixture/oral liquid/syrup
Get the arbitrary described medicine of embodiment 1-30, add 8-11 times of water gaging, decoct 3 hours, leach medicine juice.Add again 8 times of water gagings, decoct 3 hours, leach medicine juice, merge secondary decocting liquid, standing, leaching supernatant, concentrated, let cool, add 3.5 times of amount ethanol of concentrated solution, stir precipitation and spend the night.Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids, make mixture, oral liquid or syrup.
the clinical trial of embodiment 34 Drug therapy anxiety-depression of the present invention obstacle
1 research data and method
1.1 physical data
It is medical in Shanghai Chinese Medicine Hospital year February that selected case all derives from March, 2007-2008, by Hamilton is depressed, is diagnosed as anxiety-depression obstacle with Manifest Anxiety Scale, observes altogether 120 examples.120 examples are divided into 4 groups at random, and every group of 30 examples, are respectively one group of medicine, two groups of medicines, three groups of medicines and deanxit matched group.
One group of maximum 84 years old age of medicine, minimal ages 45 years old, the mean age is 66.58 ± 11.36 years old; Two groups of maximum 86 years old ages of medicine, minimal ages 46 years old, the mean age is 64.25 ± 11.07 years old; Three groups of maximum 85 years old ages of medicine, minimal ages 46 years old, the mean age is 63.93 ± 10.96 years old; Maximum 83 years old age of matched group, minimal ages 46 years old, the mean age is 67.30 ± 10.42 years old.According to statistics test of normality, show, 0.05, four group of data of four groups of P > meets normal distribution, uses t check, four groups of age there was no significant differences, P > 0.05.(in Table 1).
Four groups of physical data comparisons of table 1 (average ± s)
| ? | Number of cases | Mean age | The coefficient of skewness | Coefficient of kurtosis |
| One group of medicine | 30 | 66.58±11.36 | 0.51 | 0.86 |
| Two groups of medicines | 30 | 64.25±11.07 | 0.49 | 0.88 |
| Three groups of medicines | 30 | 63.93±10.96 | 0.46 | 0.84 |
| Matched group | 30 | 67.30±10.42 | 0.35 | 0.87 |
According to the morbidity prevalence of the present embodiment, analyze, the relation of age of onset and sickness rate as shown in Figure 1.As can be seen from Figure 1, it is relatively many that the crowd of 56 years old to 75 years old suffers from anxiety-depression obstacle number, belongs to age bracket occurred frequently, and this provides reference data for later clinical treatment and later clinical trial.
1.2 diagnostic criteria
1.2.1 Measuring scale assessing standard
1.2.1.1 Hamilton anxiety scale:
1. anxious mood: worry, worry, feel to have the worst thing to occur, easily excitation.
2. anxiety: tension, fatiguability, can not loosen, emotional response, easily cries, trembles, feels uneasy.
3. fear: fear that dark, stranger, a people stay alone, animal, by bus or travelling and the many occasions of people.
4. insomnia: have difficulty in going to sleep, easily wake up, sleep deeply, dreaminess, nightmare, fright at night, wake up after sense tired.
5. cognitive function: or claim memory, attention deficit disorder.Attention can not be concentrated, poor memory.
6. depressive mood: lose interest, to lack pleasant sensation, melancholy, early awakening, daytime light heavy night to like in the past.
7. musculature symptom: muscular soreness, movable dumb, muscle is twitched, limbs are twitched, One's teeth strike against each other, sound is shaken.
8. sensory system symptom: blurred vision, the heating of feeling cold, weakness sense, twinge from head to foot.
9. cardiovascular system symptoms: the beat sense, the sense of fainting, heartbeat of tachycardia, cardiopalmus, chest pain, blood vessel is left out.
10. Respiratory symptoms: uncomfortable in chest, sensation of asphyxia, sigh, dyspnea.
11. gastrointestinal symptom masters: dysphagia, belch, dyspepsia (stomachache, stomach burning pain, abdominal distention after feed, feel sick, stomach is full feels), borborygmus, suffer from diarrhoea, lose weight, constipation.
12. urogenital system symptoms: ascheturesis, urgent micturition, menolipsis, hyposexuality, ejaculation too early, erect can not, sexual impotence.
13. autonomic nervous system symptoms: xerostomia, flushing, pale, easy perspiration, easy " chicken plays pimple ", tension headache, the hairs of rising.
14. whens talks behavior performance: (1) generally show: anxiety, can not relax, uneasy, sting finger, tightly clench fist, fumble handkerchief, Facial tic, the foot that do not stop, hands shake, frown, express one's feelings stiff, muscular tension is high, Sighing respiration, pale complexion; (2) physiological performance: swallow, hiccough, resting heart rate are fast, breathe fast (more than 20 beats/min), tendon hyperreflexia, tremble, platycoria, eyelid are beated, easily perspire, exophthalmos.
Total score exceedes 29 points, may be serious anxiety; Exceed 21 points, certainly have obvious anxiety; Exceed 14 points, certainly have anxiety; Exceed 7 points, may have anxiety; As being less than 6 points, patient does not just have anxiety symptom.
1.2.1.2 Hamilton depressive scale:
1. depressive emotion: (1) is only just told when asking; (2) in interview, spontaneously express; (3) betray this emotion also can or wanting to cry from expression, posture, sound without speech; (4) patient's spontaneous speech and non-language performance (expression, action) almost show as this emotion completely.
2. guilty sense: (1) blame oneself, feel that oneself has involved other people; (2) think and oneself violated crime, or the mistake ruminating over the in the past mistake of becoming estranged; (3) think and be current disease to own wrong punishment, or have delusion of sin; (4) delusion of sin is with scolding or menace hallucination.
3. commit suiside: (1) feels to live nonsensical; (2) wish oneself to die, or often expect and dead relevant thing; (3) passive idea (suicidal thought); (4) there is serious suicide.
4. difficulty falling asleep (just section insomnia): there is difficulty falling asleep in (1) main suit, still can not fall asleep after the half an hour of going to bed.(will note the time that patient falls asleep at ordinary times); (2) main suit all has difficulty falling asleep every night.
5. insomnia-middle (stage casing insomnia): (1) sleeps shallow, many nightmares; (2) midnight, (before late 12 o'clock) once woke up (do not comprise and going to toilet).
6. early awakening (latter end insomnia): (1) has early awakening, early awakening 1 hour than usual, but can again fall asleep (should get rid of custom at ordinary times); (2) after early awakening, cannot again fall asleep.
7. work and interest: just tell when put question to (1); (2) spontaneously directly or indirectly express activity, work or study are lost interest, as feel listless, irresolute, can not adhere to maybe needing to force work or the activity of oneself going; (3) activity time reduces or effect decline, and inpatient participates in ward work every day or amusement is discontented with 3 hours; (4), because current disease quits work, hospitalizing does not participate in any activity or does not have other people to help just can not complete ward routine matter (note all can not be in hospital just make 4 scores).
8. retardance (refer to thinking and bradyphrasia, attention is difficult to concentrate, and initiative goes down): find slight retardance in (1) interview; (2) in interview, find obviously retardance; (3) difficulty is carried out in interview; (4) can not answer a question completely (numb).
9. intense: a bit restless when (1) checks; (2) obviously restless or little trick is many; (3) can not sit quietly, in inspection, once stand up; (4) rub hands, sting finger, pull hair, bite one's lips.
10. spirituality anxiety: tell when (1) is asked about; (2) spontaneously express; (3) expression and talk are betrayed obvious melancholy worry; (4) obviously terrified.
11. somatic anxieties (physiological signs that refers to anxiety, comprising: xerostomia, abdominal distention, diarrhoea, hiccough, angina abdominis, cardiopalmus, headache, Hyperventilation and sigh, and frequent micturition and perspiration): (1) is slight; (2) moderate, has sure above-mentioned symptom; (3) severe, above-mentioned symptom is serious, and impact life maybe needs to process; (4) have a strong impact on life and movable.
12. gastrointestinal symptoms: (1) loss of appetite, but do not need other people to encourage just to take food voluntarily; (2) feed needs other people to urge or asks and need to apply cathartic or digestant.
13. General Symptomies: (l) extremity, back or cervical region sense of heaviness, backache, headache, myalgia, malaise or tired; (2) symptom is obvious.
14. property symptoms (referring to hyposexuality, menoxenia etc.): (1) is slight; (2) severe; (3) can not affirm, or this is to being not suitable for (being not counted in total score) by the person of commenting.
15. hypochondriasis: (1) is too paid close attention to health; (2) turn over health problem; (3) there is nosomania; (4) nosomania of companion's hallucination.
16. lose weight: by medical history, evaluate: (1) patient tells and may lose weight; (2) certainly lose weight.By body weight record, evaluate: in (1) one week, lose weight and exceed 0.5 kilogram; In (2) one weeks, lose weight and exceed 1 kilogram.
17. insight: (0) is known own ill, shows as depression; (1) know that oneself is ill, but it is too poor to lay the blame on messes, environmental problem, worked busy, and viral infection maybe needs to have a rest; (2) deny completely ill.
Total score exceedes 24 points, may be major depression; Exceeding 17 points, may be the depression of light or medium degree; As being less than 7 points, patient does not just have depressive symptom.
1.2.2 integration evaluation
(1) symptom is slight;
(2) there is sure symptom, but do not affect life with movable;
(3) severe symptoms, need add processing, or has affected life activity;
(4) symptom is extremely heavy, has a strong impact on its life.
1.3 observe case standard
1.3.1 inclusive criteria:
Age is greater than 18 years old, and sanity can clearly be expressed own wish, and men and women does not limit.
Meet Hamilton depressive scale (HAMD) 17 item rating >=17 point, or HAS (HAMA) is evaluated the patient of >=14 points.Estimate to include in altogether 120 routine patients.
1.3.2 exclusion standard:
Do not meet primary disease diagnostic criteria; There are the internal diseases such as the serious organic heart, liver, kidney, endocrine, blood; There is serious suicidal tendency, have ethanol and drug dependence person, have age of sucking, gestation or likely the women of duration of test pregnancy; Medicine is had to the patient of allergies; IQ defectiveness person.
The standard 1.3.3 come off:
Compliance is poor, can not take medicine according to test method, and dosing or the person of changing dressings midway, transfers the manic or person that has suicidal tendency to during treatment.(one group of medicine is included 31 examples in, and wherein 1 example comes off; Two groups of medicines are included 32 examples in, and wherein 2 examples come off; Three groups of medicines are included 33 examples in, and wherein 3 examples come off; Matched group is included 32 examples in, and wherein 2 examples come off)
1.4 observational technique
1.4.1 grouping and administration
Through points 4 groups at random of screening eligibles, three groups of one group of medicine, two groups of medicines and medicines are taken respectively medicine prepared by embodiment 6, embodiment 16 and embodiment 26 every day, decoct to concentration as containing crude drug amount 0.25g/mL, each decoction sooner or later once, each serving with 100mL; Matched group is taken 1 deanxit, once a day.Medicining cycle is 6 weeks.During research, forbid taking other kinds psychosis, antidepressant antianxiety drugs.
1.4.2 clinical observation
Testing first week and testing the symptom of observing respectively patient, vital sign the 6th week.With Hamilton depressive scale (HAMD), Hamilton anxiety scale (HAMA) evaluation.
1.5 observation index
Observe patient blood pressure, heart rate, the rhythm of the heart and main suit when medical.
The untoward reaction situation of itemized record patient's drug administration, comprises time of origin, clinical symptoms, persistent period, treatment measures and extinction time.
1.6 curative effect judgment criteria
Using Hamilton depressive scale and Hamilton anxiety scale as main evaluation index, with point rate that subtracts of Hamilton scale, judge a curative effect.
Subtract a point rate=(total score after baseline total score-treatment)/baseline total score
Subtract point rate >=50% for effective, >=30% for taking a turn for the better, and < 30% is invalid.
Clinical effective+improvement=total effective rate
1.7 statistical method
With SPSS 13.0 statistical softwares, enumeration data χ
2check, measurement data is checked with t, and P<0.05 is for there being statistical significance.
2 results
Situation before 2.1 4 groups of treatments
Four groups of patients are before treatment, and anxiety integration and depressed integration are all learned check by statistics, anxiety integration P=0.30, and depressed integration P=0.83, four compare P > 0.05, are presented at before treatment, and the severity extent of each group is without significant difference.(in Table 2)
State of an illness comparison before four groups of treatments of table 2
Comparable situation before and after 2.2 4 groups of treatments
One group of patient anxiety of medicine treats foreset and is divided into 17.36 ± 2.94 points, is 9.75 ± 2.16 points after treatment, Epidemiological Analysis by statistics, t=14.58, P ﹤ 0.01; 14.41 ± 2.63 points of integrations before depressed treatment, 9.78 ± 2.92, t=7.89 after treatment, P ﹤ 0.01, illustrate that one group of medicine is at treatment anxiety and depressive disorder, there were significant differences in treatment front and back.
Two groups of patient anxieties of medicine treat foreset and are divided into 17.50 ± 2.91 points, are 9.70 ± 2.25 points after treatment, Epidemiological Analysis by statistics, t=15.77, P ﹤ 0.01; 13.83 ± 2.80 points of integrations before depressed treatment, 8.73 ± 2.42, t=9.45 after treatment, P ﹤ 0.01, illustrate that two groups of medicines are at treatment anxiety and depressive disorder, there were significant differences in treatment front and back.
Three groups of patient anxieties of medicine treat foreset and are divided into 18.32 ± 2.33 points, are 10.61 ± 2.41 points after treatment, Epidemiological Analysis by statistics, t=16.71, P ﹤ 0.01; 13.43 ± 2.81 points of integrations before depressed treatment, 8.93 ± 2.57, t=8.78 after treatment, P ﹤ 0.01, illustrate that three groups of medicines are at treatment anxiety and depressive disorder, there were significant differences in treatment front and back.
Matched group patient anxiety treats foreset and is divided into 18.33 ± 2.48 points, is 10.23 ± 2.14 points after treatment, Epidemiological Analysis by statistics, t=20.74, P ﹤ 0.01; 14.43 ± 2.75 points of integrations before depressed treatment, 9.93 ± 2.23, t=13.18 after treatment, P ﹤ 0.01, illustrates that matched group is at treatment anxiety and depressive disorder, before and after treatment, also there were significant differences.
Between group relatively, treatment group and treatment of control group anxiety disorder, four groups by statistics Epidemiological Analysis show P=0.35, P > 0.05, without significant difference.Treatment group and treatment of control group depressive disorder, four groups by statistics Epidemiological Analysis show P=0.11, P > 0.05, without significant difference.(in Table 3)
Integration contrast before and after four groups of treatments of table 3
According to subtracting point rate, evaluate the curative effect after treatment, subtract point rate >=50% for effective, >=30% for taking a turn for the better, and < 30% is invalid.After four groups of patient treatments, efficacy evaluation the results are shown in Table 4.Epidemiological Analysis by statistics, P ﹥ 0.05, illustrates the total effective rate no significant difference of three groups of one group of medicines, two groups of medicines, medicine and treatment of control group anxiety-depression obstacle.
Four groups of efficacy evaluation contrasts of table 4
2.3 4 groups of related symptoms integral contrasts
2.3.1 heart correlation intergal comparison
The comparison of heart correlation intergal, is used the integration of Hamilton anxiety scale the 9th, 10, and two integrations comprise the symptoms such as sense, the sense of fainting, heartbeat are omitted, uncomfortable in chest, sensation of asphyxia, sigh, dyspnea of beating tachycardia, cardiopalmus, chest pain, blood vessel.
First 2.98 ± 1.23 points of one group for the treatment of of medicine, latter 1.18 ± 0.85 points for the treatment of, t=8.09, P ﹤ 0.01, illustrates that before and after treatment, there were significant differences; First 2.91 ± 1.06 points of two groups of treatments of medicine, latter 1.06 ± 0.93 points for the treatment of, t=10.05, P ﹤ 0.01, illustrates that before and after treatment, there were significant differences; First 3.13 ± 1.13 points of three groups of treatments of medicine, latter 1.17 ± 0.91 points for the treatment of, t=9.29, P ﹤ 0.01, illustrates that before and after treatment, there were significant differences; First 2.63 ± 1.54 points for the treatment of of control group, latter 1.00 ± 0.87 points for the treatment of, t=7.35, P ﹤ 0.01, illustrates that before and after treatment, also there were significant differences; From the change of dividing equally, can obviously find out, in the improvement situation of heart integration, the improvement situation that medicine is three groups will be compared with matched group good (in Table 5).But four compare, P ﹥ 0.05, one group of medicine, two groups of medicines, three groups of medicines and matched group aspect treatment heart related symptoms without significant difference.
Table 5 heart correlation-integral Analysis
2.3.2 sleep correlation intergal comparison
The comparison of sleep correlation intergal, is used Hamilton anxiety scale the 5th, the integration of Hamilton depressive scale the 4th, 5, and these 3 contents comprise the obstacle of falling asleep, Depth of sleep, sleep quality.
First 5.43 ± 2.09 points of one group for the treatment of of medicine, latter 2.95 ± 1.78 points for the treatment of, t=6.85, P ﹤ 0.01, illustrates that before and after treatment, there were significant differences; First 5.29 ± 2.11 points of two groups of treatments of medicine, latter 2.74 ± 1.90 points for the treatment of, t=6.69, P ﹤ 0.01, illustrates that before and after treatment, there were significant differences; First 5.63 ± 2.14 points of three groups of treatments of medicine, latter 2.93 ± 1.63 points for the treatment of, t=7.08, P ﹤ 0.01, illustrates that before and after treatment, there were significant differences; First 4.80 ± 2.41 points for the treatment of of control group, latter 3.13 ± 1.90 points for the treatment of, t=6.65, P ﹤ 0.01, illustrates that before and after treatment, also there were significant differences; The difference of improving from four groups of sleep front and back can obviously be found out, the improvement situation that one group of medicine, two groups of medicines and medicine are three groups is obviously good a lot of compared with matched group, the total effective rate of matched group is 53.33%, the total effective rate that one group of medicine, two groups of medicines and medicine are three groups be respectively 63.33%, 66.67% and 70%(in Table 6,7), four differences of sleeping are compared, P ﹤ 0.05, one group of medicine, two groups of medicines, three groups of medicines and matched group are described, and aspect improvement sleep related symptoms, there were significant differences.
Table 6 correlation-integral Analysis of sleeping
Table 7 efficacy evaluation of sleeping
| ? | Number of cases | Effective | Take a turn for the better | Invalid | Total effective rate |
| Matched group | 30 | 3 | 13 | 14 | 53.33% |
| One group of medicine | 30 | 4 | 15 | 11 | 63.33% |
| Two groups of medicines | 30 | 4 | 16 | 10 | 66.67% |
| Three groups of medicines | 30 | 5 | 16 | 9 | 70.0% |
2.3.3 sleep and anxiety, depressed degree of association comparison
Add up this 120 routine patient and obtain sleep and anxiety, depressed degree of association, comparative result is in Table 8.From table 8, can clearly find out, although sleep and anxiety and depressed P value are all less than 0.05, think that sleep and anxiety-depression obstacle are proportionate.But as can be seen from the table, sleep and depressed degree of association P ﹤ 0.01, sleep and anxiety degree of association P ﹤ 0.05, visible sleep is more relevant to depressive disorder.
Table 8 sleep and anxiety, depressed degree of association comparison
| ? | Number of cases | Correlation coefficient | P value |
| Sleep and depressive disorder degree of association | 120 | 0.555 | 0.000 |
| Sleep and anxiety disorder degree of association | 120 | 0.288 | 0.026 |
2.4 safety analysis
Four groups there is not untoward reaction during treating, and do not occur nausea and vomiting gastrointestinal symptom, the asymptomatic case that sharply increases the weight of yet.
The present embodiment has been broken through research mode in the past, courageously use current very effective deanxit to test as a control group, proved in treatment anxiety-depression obstacle field, medicine of the present invention and Western medicine deanxit worthy opponent, but more can effectively regulate cardiac function, in addition, medicine of the present invention is pure Chinese medicine, can not produce drug dependence and safe without toxic side effect, easily by patient, be accepted.
Why evident in efficacy medicine of the present invention is, is because it is based on the sufficient traditional Chinese medical science and doctor trained in Western medicine theoretical basis, tranquilizing by nourishing the heart, liver-smoothing, qi-regulating.Specifically, Radix Bupleuri hardship, being slightly cold, is the key medicine of depressed liver-energy dispersing and QI regulating, promoting the circulation of QI to relieve pain, can resist on the one hand the spasm of gastrointestinal smooth muscle, can expand again on the other hand peripheral vessels and blood pressure lowering; Radix Paeoniae Alba bitter in the mouth, flat, tool nourishing blood to suppress the hyperactive liver, slow middle pain relieving, yin fluid astringing are received the effect of antiperspirant, scientific research also shows, it has couple central nervous system to have inhibitory action, mouse peritoneal injection paeoniflorin can reduce spontaneous activity, extend the length of one's sleep of ciclobarbital soluble, suppress to faint from fear due to the caused writhing response of lumbar injection acetic acid and antagonism pentylenetetrazole; Rhizoma Atractylodis Macrocephalae hardship, sweet, warm, invigorating the spleen and benefiting QI, dampness diuretic, hidroschesis, capable of regulating gastrointestinal motility function, enhancing human body immunity power; Spica Prunellae bitter, acrid, cold, improving eyesight, blood pressure lowering, mass dissipating and swelling eliminating can relieve inflammation or internal heat; Rhizoma Coptidis hardship, cold, nontoxic, heat clearing and damp drying, eliminating fire and detoxication; Its sweet in the mouth of Cortex Cinnamomi, pungent, hot greatly, owner's kidney channel, property master is descending, and merit can guiding fire to origin.Therefore say, for the treatment of anxiety-depression obstacle, to be not laser accunputure carry out diagnosis and treatment for the description of card to medicine of the present invention, is more pathogenetic background and the etiology and pathogenesis thereof of paying close attention to whole disease, gos deep into that it is basic, to effect a permanent cure as basis.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, do not departing under the prerequisite of the inventive method; can also make some improvement and supplement, these improvement and the supplementary protection scope of the present invention that also should be considered as.
Claims (5)
1. a medicine for the treatment of anxiety-depression obstacle, is characterized in that, it is to be made by the crude drug of following weight portion: 13 parts of Radix Bupleuri, 13 parts of the Radix Paeoniae Albas, 10 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts preparation.
2. a medicine for the treatment of anxiety-depression obstacle, is characterized in that, it is to be made by the crude drug of following weight portion: 13 parts of Radix Bupleuri, 13 parts of the Radix Paeoniae Albas, 10 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Spica Prunellaes, conventional method decocts preparation.
3. a medicine for the treatment of anxiety-depression obstacle, is characterized in that, it is to be made by the crude drug of following weight portion: 13 parts of Radix Bupleuri, 13 parts of the Radix Paeoniae Albas, 10 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Spica Prunellaes, 4.5 parts of Rhizoma Coptidis, 4.5 parts of Cortex Cinnamomis, conventional method decocts preparation.
4. according to the arbitrary described medicine of claim 1-3, it is characterized in that, the medicament of described medicine is capsule, granule, tablet, mixture or syrup.
5. according to the arbitrary described medicine of claim 1-3, it is characterized in that the application of described medicine in preparation treatment anxiety-depression obstacle medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210005314.1A CN102552436B (en) | 2012-01-10 | 2012-01-10 | Medicine for treating anxiety and depressive disorder as well as application of medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210005314.1A CN102552436B (en) | 2012-01-10 | 2012-01-10 | Medicine for treating anxiety and depressive disorder as well as application of medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102552436A CN102552436A (en) | 2012-07-11 |
| CN102552436B true CN102552436B (en) | 2014-05-07 |
Family
ID=46399891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210005314.1A Expired - Fee Related CN102552436B (en) | 2012-01-10 | 2012-01-10 | Medicine for treating anxiety and depressive disorder as well as application of medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102552436B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105381015A (en) * | 2015-11-26 | 2016-03-09 | 天津中医药大学 | Traditional Chinese medicine composition with anti-depression function and preparation method thereof |
| CN106362078A (en) * | 2016-11-04 | 2017-02-01 | 上海市中医医院 | Antianxiety traditional Chinese medicine composition and application thereof |
| CN112426503B (en) * | 2019-11-29 | 2022-09-23 | 王宇红 | Traditional Chinese medicine composition for treating depression |
| CN113663009A (en) * | 2020-05-13 | 2021-11-19 | 鹤壁市人民医院 | Pharmaceutical composition for regulating nerves as well as preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1810274A (en) * | 2005-01-28 | 2006-08-02 | 郑乐建 | Cassia, its extract cinnamal and their application in preparing medicine for treating depression |
| CN101244244A (en) * | 2008-03-05 | 2008-08-20 | 四川省中医药科学院 | Depression treating medicine composition and preparation method thereof |
| CN102058691A (en) * | 2010-11-23 | 2011-05-18 | 河南中医学院 | Application of coptis and alkaloid thereof in preparation of anti-anxiety medicament |
| CN102283910A (en) * | 2011-08-05 | 2011-12-21 | 浙江省中医药研究院 | Chinese medicinal composition with anti-depression effect and preparation and preparation method thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1123357C (en) * | 1999-06-25 | 2003-10-08 | 刘永香 | Powdered medicine for conditioning viscera and whole body |
| US8252290B2 (en) * | 2008-03-04 | 2012-08-28 | Vita Green Health Products Company Limited | Herbal composition for treatment of insomnia and other related disorders and a method of preparing the same |
| CN101411800B (en) * | 2008-12-01 | 2010-12-29 | 唐振坤 | Medicament for treating anxiety symptoms |
| CN101711847B (en) * | 2009-12-08 | 2011-12-21 | 中国人民解放军第三医院 | Oral traditional Chinese medicine preparation for treating melancholia and anxiety neurosis |
| CN102008561B (en) * | 2010-12-09 | 2012-04-18 | 上海市精神卫生中心 | Mixture for treating depression |
| CN102078520B (en) * | 2011-01-10 | 2012-07-04 | 董春玲 | Chinese medicinal preparation for treating nervous headache and preparation method thereof |
| CN102580019A (en) * | 2011-01-14 | 2012-07-18 | 天津市中宝制药有限公司 | Chinese medicinal composition for treating reflux esophagitis |
| CN102133378B (en) * | 2011-03-23 | 2012-02-29 | 何玉伟 | Medicament for treating breast cancer |
| CN102139086B (en) * | 2011-04-09 | 2012-03-28 | 河南中医学院 | Traditional Chinese medicine for treating liver stagnation and spleen deficiency type post-stroke depression |
| CN102319406B (en) * | 2011-10-10 | 2013-05-15 | 张运林 | Medicament for treating tristimania |
| CN102406821B (en) * | 2011-10-26 | 2013-10-09 | 刘运波 | Traditional Chinese medicine for treating simple goiter |
| CN102406894B (en) * | 2011-11-08 | 2013-12-04 | 刘运波 | Chinese medicine for treating premenstrual syndrome |
| CN102416145B (en) * | 2011-12-07 | 2014-04-16 | 毕华妮 | Chinese medicinal composition for treating menstrual disorder |
-
2012
- 2012-01-10 CN CN201210005314.1A patent/CN102552436B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1810274A (en) * | 2005-01-28 | 2006-08-02 | 郑乐建 | Cassia, its extract cinnamal and their application in preparing medicine for treating depression |
| CN101244244A (en) * | 2008-03-05 | 2008-08-20 | 四川省中医药科学院 | Depression treating medicine composition and preparation method thereof |
| CN102058691A (en) * | 2010-11-23 | 2011-05-18 | 河南中医学院 | Application of coptis and alkaloid thereof in preparation of anti-anxiety medicament |
| CN102283910A (en) * | 2011-08-05 | 2011-12-21 | 浙江省中医药研究院 | Chinese medicinal composition with anti-depression effect and preparation and preparation method thereof |
Non-Patent Citations (10)
| Title |
|---|
| 交泰丸抗抑郁作用的药理实验研究;吴琨等;《贵阳中医学院学报》;20090930;第31卷(第5期);29-31页，尤其是29页左栏第1段 * |
| 刘冬等.半夏夏枯草合剂对慢性应激抑郁模型大鼠血清皮质醇的影响.《贵阳中医学院学报》.2010,第32卷(第1期),22-23页，尤其是22页摘要. |
| 半夏夏枯草合剂对慢性应激抑郁模型大鼠血清皮质醇的影响;刘冬等;《贵阳中医学院学报》;20100131;第32卷(第1期);22-23页，尤其是22页摘要 * |
| 吴琨等.交泰丸抗抑郁作用的药理实验研究.《贵阳中医学院学报》.2009,第31卷(第5期),29-31页，尤其是29页左栏第1段. |
| 夏枯草镇静与催眠作用的初步研究;赵江丽等;《时珍国医国药》;20091231;第20卷(第2期);443-444页，尤其是443页摘要 * |
| 方善光.痛泻要方加味治疗肠道易激综合征.《中国中医药信息杂志》.2000,第7卷(第5期),61页"5讨论"第14-16行. |
| 王静.调和肠激停汤治疗肠易激综合征35例疗效观察.《河北中医》.2010,第32卷(第1期),50-51页，尤其是51页左栏最后1段. |
| 痛泻要方加味治疗肠道易激综合征;方善光;《中国中医药信息杂志》;20001231;第7卷(第5期);61页"5讨论"第14-16行 * |
| 调和肠激停汤治疗肠易激综合征35例疗效观察;王静;《河北中医》;20100131;第32卷(第1期);50-51页，尤其是51页左栏最后1段 * |
| 赵江丽等.夏枯草镇静与催眠作用的初步研究.《时珍国医国药》.2009,第20卷(第2期),443-444页，尤其是443页摘要. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102552436A (en) | 2012-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101766791B (en) | Chinese herbal composite for fever treatment and preparation method thereof | |
| CN101670076B (en) | Traditional Chinese medicine composition for treating disease of chronic nephritis and preparation method thereof | |
| CN101711850B (en) | Traditional Chinese medicine composition for treating symptoms of myocardial ischemia, palpitation and severe palpitation and preparation method | |
| CN102526474B (en) | Chinese medicine composition for treating neurasthenia | |
| CN101773650A (en) | Chinese medicinal composition for treating clonic convulsion and preparation method thereof | |
| CN103800639A (en) | Medicinal composition with blood glucose reducing, blood lipid reducing and blood pressure lowering effects | |
| CN102240380B (en) | Traditional Chinese medicine preparation for treating senile vascular dementia | |
| CN101670060A (en) | Traditional Chinese medicine composition for treating such diseases as hepatic stagnation, chest stuffiness and distension and preparation method | |
| CN101711847B (en) | Oral traditional Chinese medicine preparation for treating melancholia and anxiety neurosis | |
| CN102552436B (en) | Medicine for treating anxiety and depressive disorder as well as application of medicine | |
| CN103520640B (en) | Traditional Chinese medicine for treating depression | |
| CN101810787B (en) | Chinese medicinal composition for treating dysphoria and preparation method thereof | |
| CN104983985B (en) | A kind of Chinese medicine preparation of Cure of depression | |
| CN101711853B (en) | Traditional Chinese medicine composition for treating symptoms of bradycardia and preparation method thereof | |
| CN101856483B (en) | Chinese medicinal composition for treating intermenstrual abnormal emotion and preparation method thereof | |
| CN1325099C (en) | Mine-tranquilizing soporific capsule | |
| CN101773652B (en) | Chinese medicine composition for treating amnesia and preparation method thereof | |
| CN102091231B (en) | Traditional Chinese medicine composition for treating neurasthenia | |
| CN101791348B (en) | Traditional Chinese medicine preparation for treatment of deficiency of five viscera | |
| CN103007214A (en) | Chinese medicinal composition for treating palpitation | |
| CN103550470B (en) | Healthy traditional Chinese medicine for children | |
| CN104906551A (en) | Anti-fatigue traditional Chinese medicine, food composition and preparation method | |
| CN101549124A (en) | Pharmaceutical composition for nourishing heart, tranquillization, strengthening spleen and benefiting qi and preparation method thereof | |
| Fruehauf | Mental Disorders | |
| CN102872292A (en) | Traditional Chinese medicine for curing spleen and kidney deficiency type ischemic post-stroke depression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140507 Termination date: 20160110 |